Burning Rock narrows losses with drug research as new driver
The cancer testing company has finally reduced the flow of red ink and is generating a growing income stream from drug research services Key Takeaways: Burning Rock's net loss…
BNR.US
Family control takes bite out of Modern Dental Group
The dental prosthetics company’s revenue jumped 18.3% in first quarter, but its domination by a single family may be limiting its appeal to investors Key Takeaways: Modern Dental Group’s revenue…
3600.HK
Profits recover at Alibaba Health but prognosis unclear
The digital pharmacy and healthcare provider returned to profit in the last fiscal year but is still struggling to limit its reliance on drug sales Key Takeaways: Alibaba Health delivered…
0241.HK
Medical imaging group Rimag sets growth focus with IPO
Buoyed by a healthcare boom, the provider of medical imaging services has filed to list on the Hong Kong Stock Exchange. Key Takeaways: Revenues have been rising at Rimag Group,…
CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
2616.HK
BeiGene goes for global growth with sales and R&D push
The maker of cancer drugs is ploughing most of its rising revenues into research and sales, as it prioritizes expansion over profits for now Key Takeaways: BeiGene’s revenue in the…
BGNE.US
6160.HK
Missing the Covid boat, Junshi stumbles back to old business
Despite developing an oral drug to treat Covid, the biotech company's revenue fell sharply and its net loss widened by nearly 40% in the first quarter Key Takeaways: Junshi Bioscience's…
1877.HK
688180.SHG
